Suppr超能文献

组织蛋白酶D原激活与成熟的结构要求。

Structural requirements of procathepsin D activation and maturation.

作者信息

Richo G R, Conner G E

机构信息

Department of Cell Biology and Anatomy, University of Miami School of Medicine, Florida 33101.

出版信息

J Biol Chem. 1994 May 20;269(20):14806-12.

PMID:8182087
Abstract

Cathepsin D biosynthesis involves several proteolytic events; however, the enzymology and sequence of these events are not known. Procathepsin D undergoes a pH-dependent, intramolecular proteolysis in vitro which removes 26 residues yielding an active form that is intermediate in size between procathepsin D and single-chain cathepsin D. This form, designated pseudocathepsin D, has not been shown to be an in vivo intermediate. The N-terminal sequence of the light chain of cathepsin D, isolated from human placenta, showed that 42 residues were removed as compared with 44 residues predicted by comparison with porcine cathepsin D. Site-directed mutations were generated at both processing sites within the propeptide of procathepsin D. Mutation at the autocatalytic site prevented in vitro autoactivation, but, after transfection of mouse Ltk- cells, the mutant procathepsin D was transported to the lysosome and processed normally to the mature enzyme despite its inability to autoactivate in vitro. Mutation at the mature N terminus of cathepsin D prevented in vivo formation of the single-chain form of the enzyme; however, the protein was still processed to the two-chain form of human cathepsin D. This change at the mature N terminus did not prevent in vitro autoactivation. Procathepsin D with mutations at both cleavage sites was processed to the two-chain form despite the inability to undergo removal of the propeptide. These results indicated that stepwise autoactivation and propeptide removal were not necessary for later processing or delivery of human cathepsin D to the lysosome. The results also suggested that pseudocathepsin D was not a normal intermediate of procathepsin D processing in vivo.

摘要

组织蛋白酶D的生物合成涉及多个蛋白水解事件;然而,这些事件的酶学及顺序尚不清楚。组织蛋白酶原D在体外经历pH依赖性的分子内蛋白水解,去除26个残基,产生一种活性形式,其大小介于组织蛋白酶原D和单链组织蛋白酶D之间。这种形式,称为假组织蛋白酶D,尚未被证明是体内的中间体。从人胎盘中分离出的组织蛋白酶D轻链的N端序列显示,与通过与猪组织蛋白酶D比较预测的44个残基相比,有42个残基被去除。在组织蛋白酶原D的前肽内的两个加工位点都产生了定点突变。自催化位点的突变阻止了体外自激活,但是,在转染小鼠Ltk-细胞后,突变的组织蛋白酶原D被转运到溶酶体并正常加工成成熟酶,尽管它在体外无法自激活。组织蛋白酶D成熟N端的突变阻止了该酶单链形式的体内形成;然而,该蛋白仍被加工成人类组织蛋白酶D的双链形式。成熟N端的这种变化并未阻止体外自激活。尽管无法去除前肽,但在两个切割位点都有突变的组织蛋白酶原D仍被加工成双链形式。这些结果表明,逐步自激活和前肽去除对于人类组织蛋白酶D随后加工或转运至溶酶体并非必要。结果还表明,假组织蛋白酶D不是组织蛋白酶原D在体内加工的正常中间体。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验